vTv Therapeutics (VTVT) Competitors

Nuvectis Pharma has lower revenue, but higher earnings than vTv Therapeutics. vTv Therapeutics is trading at a lower price-to-earnings ratio than Nuvectis Pharma, indicating that it is currently the more affordable of the two stocks.

vTv Therapeutics' return on equity of 3.96% beat Nuvectis Pharma's return on equity.

vTv Therapeutics has a beta of 0.25, indicating that its share price is 75% less volatile than the broader market. Comparatively, Nuvectis Pharma has a beta of -0.24, indicating that its share price is 124% less volatile than the broader market.

17.5% of vTv Therapeutics shares are held by institutional investors. Comparatively, 96.8% of Nuvectis Pharma shares are held by institutional investors. 6.0% of vTv Therapeutics shares are held by insiders. Comparatively, 28.6% of Nuvectis Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Nuvectis Pharma had 2 more articles in the media than vTv Therapeutics. MarketBeat recorded 3 mentions for Nuvectis Pharma and 1 mentions for vTv Therapeutics. vTv Therapeutics' average media sentiment score of 1.89 beat Nuvectis Pharma's score of 0.90 indicating that vTv Therapeutics is being referred to more favorably in the media.

vTv Therapeutics presently has a consensus price target of $55.33, suggesting a potential upside of 75.22%. Nuvectis Pharma has a consensus price target of $35.00, suggesting a potential upside of 89.80%. Given Nuvectis Pharma's higher probable upside, analysts clearly believe Nuvectis Pharma is more favorable than vTv Therapeutics.

Neurogene has a beta of 1.68, suggesting that its share price is 68% more volatile than the broader market. Comparatively, vTv Therapeutics has a beta of 0.25, suggesting that its share price is 75% less volatile than the broader market.

vTv Therapeutics has higher revenue and earnings than Neurogene. vTv Therapeutics is trading at a lower price-to-earnings ratio than Neurogene, indicating that it is currently the more affordable of the two stocks.

52.4% of Neurogene shares are held by institutional investors. Comparatively, 17.5% of vTv Therapeutics shares are held by institutional investors. 11.7% of Neurogene shares are held by company insiders. Comparatively, 6.0% of vTv Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

vTv Therapeutics' return on equity of 3.96% beat Neurogene's return on equity.

In the previous week, Neurogene had 5 more articles in the media than vTv Therapeutics. MarketBeat recorded 6 mentions for Neurogene and 1 mentions for vTv Therapeutics. vTv Therapeutics' average media sentiment score of 1.89 beat Neurogene's score of 0.33 indicating that vTv Therapeutics is being referred to more favorably in the news media.

Neurogene presently has a consensus price target of $84.83, suggesting a potential upside of 121.38%. vTv Therapeutics has a consensus price target of $55.33, suggesting a potential upside of 75.22%. Given Neurogene's stronger consensus rating and higher probable upside, equities research analysts clearly believe Neurogene is more favorable than vTv Therapeutics.

vTv Therapeutics presently has a consensus price target of $55.33, suggesting a potential upside of 75.22%. Valneva has a consensus price target of $11.98, suggesting a potential upside of 127.66%. Given Valneva's higher possible upside, analysts clearly believe Valneva is more favorable than vTv Therapeutics.

vTv Therapeutics has a net margin of 0.00% compared to Valneva's net margin of -88.87%. vTv Therapeutics' return on equity of 3.96% beat Valneva's return on equity.

In the previous week, Valneva had 4 more articles in the media than vTv Therapeutics. MarketBeat recorded 5 mentions for Valneva and 1 mentions for vTv Therapeutics. vTv Therapeutics' average media sentiment score of 1.89 beat Valneva's score of 0.44 indicating that vTv Therapeutics is being referred to more favorably in the media.

vTv Therapeutics has a beta of 0.25, indicating that its share price is 75% less volatile than the broader market. Comparatively, Valneva has a beta of 1.77, indicating that its share price is 77% more volatile than the broader market.

vTv Therapeutics has higher earnings, but lower revenue than Valneva. vTv Therapeutics is trading at a lower price-to-earnings ratio than Valneva, indicating that it is currently the more affordable of the two stocks.

17.5% of vTv Therapeutics shares are held by institutional investors. Comparatively, 11.4% of Valneva shares are held by institutional investors. 6.0% of vTv Therapeutics shares are held by company insiders. Comparatively, 14.9% of Valneva shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Tilray Brands had 22 more articles in the media than vTv Therapeutics. MarketBeat recorded 23 mentions for Tilray Brands and 1 mentions for vTv Therapeutics. vTv Therapeutics' average media sentiment score of 1.89 beat Tilray Brands' score of 0.78 indicating that vTv Therapeutics is being referred to more favorably in the news media.

vTv Therapeutics has a net margin of 0.00% compared to Tilray Brands' net margin of -156.51%. vTv Therapeutics' return on equity of 3.96% beat Tilray Brands' return on equity.

Tilray Brands presently has a consensus price target of $11.50, suggesting a potential upside of 157.85%. vTv Therapeutics has a consensus price target of $55.33, suggesting a potential upside of 75.22%. Given Tilray Brands' higher possible upside, research analysts clearly believe Tilray Brands is more favorable than vTv Therapeutics.

9.4% of Tilray Brands shares are owned by institutional investors. Comparatively, 17.5% of vTv Therapeutics shares are owned by institutional investors. 0.8% of Tilray Brands shares are owned by insiders. Comparatively, 6.0% of vTv Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

vTv Therapeutics has lower revenue, but higher earnings than Tilray Brands. vTv Therapeutics is trading at a lower price-to-earnings ratio than Tilray Brands, indicating that it is currently the more affordable of the two stocks.

Tilray Brands has a beta of 1.89, suggesting that its stock price is 89% more volatile than the broader market. Comparatively, vTv Therapeutics has a beta of 0.25, suggesting that its stock price is 75% less volatile than the broader market.